CLV Stock Overview
Clover Corporation Limited refines and sells natural oils in Australia, New Zealand, Asia, Europe, and the Americas.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.09|
|52 Week High||AU$1.80|
|52 Week Low||AU$0.95|
|1 Month Change||5.85%|
|3 Month Change||-17.80%|
|1 Year Change||-35.03%|
|3 Year Change||-51.78%|
|5 Year Change||133.33%|
|Change since IPO||210.00%|
Recent News & Updates
Here's Why Clover (ASX:CLV) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|CLV||AU Chemicals||AU Market|
Return vs Industry: CLV underperformed the Australian Chemicals industry which returned 10.5% over the past year.
Return vs Market: CLV underperformed the Australian Market which returned -4.9% over the past year.
|CLV Average Weekly Movement||6.9%|
|Chemicals Industry Average Movement||11.9%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.8%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: CLV is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CLV's weekly volatility (7%) has been stable over the past year.
About the Company
Clover Corporation Limited refines and sells natural oils in Australia, New Zealand, Asia, Europe, and the Americas. It also engages in the production of encapsulated powders; and research and product development of functional food and infant nutrition ingredients. The company offers Nu-Mega Hi docosahexaenoic tuna oils for use in infant formula and pharmaceutical products; Ocean Gold refined tuna oils; Nu-Mega Driphorm powders that are used in a range of infant formula, follow-on formula, growing up milks, and food applications; and Nu-Mega Driphorm HA for non-dairy applications.
Clover Fundamentals Summary
|CLV fundamental statistics|
Is CLV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLV income statement (TTM)|
|Cost of Revenue||AU$42.39m|
Last Reported Earnings
Jan 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.033|
|Net Profit Margin||9.05%|
How did CLV perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is CLV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLV?
Other financial metrics that can be useful for relative valuation.
|What is CLV's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CLV's PE Ratio compare to its peers?
|CLV PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ANO Advance ZincTek
DGL DGL Group
ZNO Zoono Group
BRL Bathurst Resources
Price-To-Earnings vs Peers: CLV is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the peer average (30.1x).
Price to Earnings Ratio vs Industry
How does CLV's PE Ratio compare vs other companies in the Global Chemicals Industry?
Price-To-Earnings vs Industry: CLV is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the Global Chemicals industry average (16.2x)
Price to Earnings Ratio vs Fair Ratio
What is CLV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||32.8x|
|Fair PE Ratio||20.4x|
Price-To-Earnings vs Fair Ratio: CLV is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the estimated Fair Price-To-Earnings Ratio (20.4x).
Share Price vs Fair Value
What is the Fair Price of CLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CLV (A$1.09) is trading above our estimate of fair value (A$0.34)
Significantly Below Fair Value: CLV is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Clover forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLV's forecast earnings growth (26.6% per year) is above the savings rate (1.8%).
Earnings vs Market: CLV's earnings (26.6% per year) are forecast to grow faster than the Australian market (6.2% per year).
High Growth Earnings: CLV's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLV's revenue (16.3% per year) is forecast to grow faster than the Australian market (5% per year).
High Growth Revenue: CLV's revenue (16.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLV's Return on Equity is forecast to be low in 3 years time (12.6%).
Discover growth companies
How has Clover performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLV has high quality earnings.
Growing Profit Margin: CLV's current net profit margins (9%) are lower than last year (12.9%).
Past Earnings Growth Analysis
Earnings Trend: CLV's earnings have grown by 12.2% per year over the past 5 years.
Accelerating Growth: CLV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CLV had negative earnings growth (-46.9%) over the past year, making it difficult to compare to the Chemicals industry average (196.9%).
Return on Equity
High ROE: CLV's Return on Equity (9.3%) is considered low.
Discover strong past performing companies
How is Clover's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CLV's short term assets (A$54.5M) exceed its short term liabilities (A$7.9M).
Long Term Liabilities: CLV's short term assets (A$54.5M) exceed its long term liabilities (A$11.5M).
Debt to Equity History and Analysis
Debt Level: CLV's net debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CLV's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CLV's debt is well covered by operating cash flow (27.3%).
Interest Coverage: CLV's interest payments on its debt are well covered by EBIT (20.6x coverage).
Discover healthy companies
What is Clover current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLV's dividend (0.92%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.63%).
High Dividend: CLV's dividend (0.92%) is low compared to the top 25% of dividend payers in the Australian market (6.42%).
Stability and Growth of Payments
Stable Dividend: CLV is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CLV is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: CLV is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: CLV is not paying a notable dividend for the Australian market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Peter J. Davey, MBA, GradDip Bus., Dip Art(Design), GAICD, has been Chief Executive Officer and Managing Director of Clover Corporation Limited since November 11, 2014. Mr. Davey has held senior manage...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD418.49K) is above average for companies of similar size in the Australian market ($USD280.16K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: CLV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: CLV's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clover Corporation Limited's employee growth, exchange listings and data sources
- Name: Clover Corporation Limited
- Ticker: CLV
- Exchange: ASX
- Founded: 1988
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: AU$180.587m
- Shares outstanding: 166.44m
- Website: https://www.clovercorp.com.au
Number of Employees
- Clover Corporation Limited
- 39 Pinnacle Road
- Altona North
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/19 00:00|
|End of Day Share Price||2022/08/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.